Jonathan Silverstein Chairman of the Board [+]
Mr. Silverstein is a General Partner of OrbiMed, the world’s largest fully dedicated healthcare fund manager with several billion in assets under management. Mr. Silverstein joined OrbiMed in 1998 to focus on private equity and structured transactions in small capitalization public biotechnology and medical device companies. Mr. Silverstein was previously a Director of Life Sciences in the Investment Banking Department at Sumitomo Bank. During his tenure at Sumitomo, he was in charge of strategic alliances, mergers and acquisitions in the biotech sector. Mr. Silverstein has a J.D. and an M.B.A. from the University of San Diego, and a B.A. in Economics from Denison University. Currently, Mr. Silverstein is the Chairman of Gelesis and Cerapedics and a Director of SuperDimension, Nxstage Medical (NTXTM), and Glaukos. He has been a former director or observer in an additional dozen companies including: LifeCell (LIFC), Given Imaging (GIVN), Cerexa (sold to Forest Labs), Peninsula Pharmaceuticals (sold to JNJ), Predix (sold to EPIX), Avanir (AVNR), Orthovita (VITA), Auxillium (AUXL), Bioenvision (BIVN), and Adiana (sold to Cytyc).
David Bonita [+]
Private Equity Principal, OrbiMed Advisors. Dr. Bonita joined OrbiMed in 2004 to focus on private equity investments and structured transactions in small capitalization public equity companies. Prior to joining OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has also published scientific articles in peer reviewed journals based on signal transduction research performed at the Harvard Medical School. Dr. Bonita received his A.B. degree magna cum laude in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society. Dr. Bonita currently serves as a director on the board of ViewRay. He has also served or currently serves as an observer on the boards of Roka Bioscience, Ambit Biosciences, SuperDimension, and Insulet, and is actively involved in OrbiMed's investments in NxStage Medical and Volcano Corporation.
Robert Heft [+]
Upon completion of his doctorate at the Massachusetts Institute of Technology in 1986, Dr. Heft joined Continental Pharma Cryosan as its Research Director. Shortly thereafter, he founded IBEX Technologies (Montreal, Quebec) and served as its President until 2001. In 2001, Dr. Heft joined BioMarin Pharmaceutical Inc. (Novato, California) as Vice-President Product Development, after BioMarin acquired the pharmaceutical assets of IBEX. Dr. Heft joined Enobia as President and CEO in 2005. Dr. Heft has served as a Director of the Industrial Biotechnology Association of Canada, the Canadian Genetic Disease Network and of BioCapital a life-sciences venture fund.
M. Luc Mainville [+]
Mr. Mainville currently serves as the Chairman of Alethia Biotherapeutics and Powertech Canada. During his career, Mr. Mainville has held executives positions for various private and public companies including LAB International Inc., URRMA Biopharma, RTP Pharma and Waratah Pharmaceuticals which he co-founded and brought public in 2000. Previous to 1998, Mr. Mainville was Senior Vice President and Partner in the corporate finance group of KPMG. Mr. Mainville holds an MBA degree as well as Bachelor’s degree in Finance. Mr. Mainville is also member of the Board of Directors of BioteCanada and Power Tech Corporation (TSXV:PWB).
Richard Meadows [+]
Richard Meadows is a Managing Partner with CTI Life Sciences Fund and one of its co-founders. He joined the Fund from his previous position as a Venture Partner with VantagePoint Venture Partners, a US$2.8 billion private Equity fund based in San Bruno California. Richard was also a Partner in the Biotechnology Group of CDP Capital Technology Ventures ($1.2 billion). He has extensive experience in operations, general management in biopharmaceuticals, and finance. Richard has made and managed investments in the cancer, cardiovascular, auto-inflammatory and immunology areas. Through these investments, he has represented investors on some 12 Company Boards and counting.
Fredric Price [+]
Fredric D. Price was elected to our Board of Directors in May 2006. He is currently also Chairman of the Board of Directors and CEO of Chiasma and Executive Chairman of the Board of Directors of Peptimmune. In May 2008, he stepped down after 4 years as chairman of the board of directors of Omrix Biopharmaceuticals and in March 2010 he stepped down after 3 years on the board of Pharmasset. Previously, he was chairman of the board of directors and CEO of BioMarin Pharmaceutical. As chairman and/or CEO, he has raised more than $500 million in a variety of securities transactions, led a total of 18 M&A and licensing transactions, built FDA approved facilities and had drugs approved in the US as well as in international markets. His earlier experience includes having been president, CEO and a member of the board of directors of Applied Microbiology, vice president of finance and administration and CFO of Regeneron Pharmaceuticals, the founder of the strategy consulting firm RxFDP, and vice president of Pfizer Pharmaceuticals with both line and staff responsibilities. Mr. Price is a co-inventor of 13 issued US patents. He received a BA from Dartmouth College and an MBA from the Wharton School of the University of Pennsylvania.
Dr. Thomas J. Schuetz has over 8 years of experience leading clinical development programs from Phase 1 through Phase 4 at both public and privately-held biopharmaceutical companies. Dr. Schuetz was previously the CMO of Therion Biologics Corporation and was the Vice President of Clinical Affairs at Transkaryotic Therapies, Inc. (TKT), where he lead the clinical development of Replagal® for the treatment of Fabry disease and Elaprase® for the treatment of Hunter Syndrome. Dr. Schuetz holds an MD degree from Harvard Medical School, cum laude, and a PhD in Genetics from Harvard University. He did an internal medicine residency at Massachusetts General Hospital, where he was also Chief Medical Resident, and a Medical Oncology fellowship at the Dana-Farber Cancer Institute, both in Boston. He is Board Certified in Internal Medicine and Medical Oncology.